• FDA Introduces FAERS to Report Drugs and Biologics Adverse Events

    Are you a drug or biologics manufacturer willing to submit adverse event (AE) report with respect to your product to the United States Food and Drug Administration (USFDA)? Or are you a healthcare professional or a consumer planning to report AE or medication error to the US health agency and/or willing to access the safety information related to a specific drug? Then, here is an announcement for you. The USFDA, on 27th Sep 2017, has officially launched searchable public dashboard for its drugs and biologics AE database.

  • End-to-End Regulatory Services

    Overview

    The Life Sciences market is growing and is expected to reach US$ 4,200 Million by the end of 2024. At the same time, the world is turning more protective about increasing health concerns. Alongside addressing the health needs and aligning with the market scenario, the pharma, biotech, cosmetic, medical devices and healthcare organizations shouldn’t only innovate new compliant products, but also ensure that they are accessible across the globe with stringent safety and efficacy measures.

  • Pharmacovigilance Signal Detection Management Services

     

    Pharmacovigilance Signal Detection Management Services – Overview

    The pharmacovigilance signal detection management process is a set of activities performed to determine whether there are new risks associated with a medicinal product or whether known risks have changed based on the examination of Individual Case Safety Reports (ICSRs), aggregated data from active surveillance systems or studies, and scientific literature information or other data sources.

  • Individual Case Safety Report (ICSR) Services

     

    Individual Case Safety Report (ICSR) Services – Overview

    Individual Case Safety Report (ICSR) standard varies with every product type. With the continuous increase in ADR cases from various sources resulting from research and development, there is always a need to align with improved ICSR case processing standards and regulations. In such scenarios, to comply with the Health Authority (HA) requirements, organizations might opt for specialized ICSR Pharmacovigilance services in accordance with the adverse event reporting system.

  • Aggregate Safety Reports Services

     

    Aggregate Safety Reports Services - Overview

    To protect the safety and efficacy of a drug, the Marketing Authorization Holder (MAH) must conduct pharmacovigilance aggregate reporting and safety writing and periodically submit the aggregate safety reports, also known as periodic reports or periodic safety reports, to the Health Authorities (HAs).

  • Non-Clinical Regulatory Writing Services

     

    Non-Clinical Regulatory Writing Services – An Overview

    Non-clinical medical writing strategy plays a crucial role in drug development. A well-planned pre-clinical drug development strategy not only saves time and money in the lead compound development but also helps to identify failed compounds at the early developmental stages. A Regulatory expert providing seasoned expertise concerning Non-clinical Regulatory writing services can make such a revolution.

  • Clinical Trial Audit and Monitoring Services

     

    Clinical Trial Audit and Monitoring Services - Overview

    Clinical trial audits and clinical trial monitoring guarantee that the trial data is accurate, complete, verifiable, and in agreement with ethical and scientific norms. Clinical trial monitoring quality is the basis for efficient execution, and the success of each clinical trial depends on it. Robust clinical trial monitoring is vital to protect the integrity of the scientific data and yield valid Regulatory data.

  • Clinical Trial and Consulting Services

     

    Clinical Trial and Consulting Services - Overview

    Submission of documents post clinical research for Health Authority (HA) review requires specialized skill in clinical study report writing. Clear and precise clinical study report (CSR) writing helps reviewers comprehend the technicalities of clinical research, as a single error in clinical documentation may prove risky and costly for organizations, causing approval delays.